$EXC

ComEd's $15 billion grid plan fuels questionable spending

Exelon’s ComEd is seeking approval for a $15.3 billion, four-year grid plan in Illinois. The Citizens Utility Board says filings include over $1 billion in inflated or mislabeled spending, including $238 million in peak-demand estimates, $209.4 million smart meter replacements, and $124 million EV charging cost assumptions. CUB alleges discretionary costs were labeled “mandatory” to skirt CEJA.

Original reporting
Published Jul 29, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 1:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ComEd's $15 billion grid plan fuels questionable spending — source image
Decision brief

The 30-second read

$EXCBearishMed
01

Why it matters

The article reports CUB expert testimony alleging more than $1B of spending in ComEd’s $15.3B, four-year grid plan is inflated, unjustified, or mislabeled, including smart meter replacements, EV charging cost estimates, and discretionary spending categorized as mandatory under CEJA.

02

Market read

Traders may reassess the risk of adverse Illinois regulatory outcomes for Exelon’s allowed spend and customer bill impacts as the case approaches October’s proposed order.

03

What to watch

The article does not quantify the probability of commission rejection of each line item, nor does it show Exelon’s rebuttal or the full evidentiary record beyond CUB’s expert testimony.

Relevance 6/10Novelty 5/10Timing: Ahead of the Illinois Commerce Commission’s proposed order expected in October.

Background

Exelon launched “The Exelon Promise” in February, pledging to protect customers regardless of market conditions and to ensure large energy users pay their fair share of grid investments.

Company-level read

Ticker impact

$EXCBearishMedium confidence
Context

The article alleges Exelon’s ComEd grid plan includes over $1B in inflated or mislabeled spending, including smart meter replacements and EV cost assumptions.

Expected impact

Near-term downside bias for EXC on risk of adverse Illinois Commerce Commission findings or required plan revisions.

Evidence & confidence

The piece centers on expert testimony challenging cost categories (mandatory vs discretionary) and specific line items, with a proposed order expected in October and final by year-end.

Market effects

Highlights heightened regulatory scrutiny of utility capital spending classification under CEJA, which can raise compliance and allowed-spend uncertainty for other regulated utilities.

Illinois rate-case outcomes can influence local utility sentiment and expectations for customer bill trajectories.

Limited direct global impact, but it reinforces a broader theme of regulatory cost recovery risk in US regulated utilities.

Counterpoint

Expert testimony is not a final ruling; ComEd may argue the challenged items are necessary, and the commission could still approve most of the plan.

Key entities

  • Exelon

    Parent company of ComEd, whose Illinois grid plan is under scrutiny in the article.

  • ComEd

    Illinois utility proposing a $15.3B, four-year grid plan challenged by expert testimony.

  • Citizens Utility Board (CUB)

    Filed expert testimony alleging inflated or mislabeled spending and CEJA compliance issues.

  • Illinois Commerce Commission

    Expected to issue a proposed order in October and a final order by year-end.

Related articles

$EXCMedAI 8/10

Exelon (EXC) Q2 2026 Earnings Call Transcript

Exelon (EXC) reported Q2 2026 adjusted operating earnings of $0.43 per share and reaffirmed full-year guidance of $2.81 to $2.91 per share, according to its earnings call transcript. Management cited storm impacts on ComEd and PHI, regulatory progress in rate cases, and PJM capacity and price signals amid rising demand and tight supply.

$EXCMed

Exelon Corporation Q2 2026 Earnings Call Summary

Exelon reported Q2 2026 earnings call updates, citing higher distribution and transmission rates and fewer prior-year customer relief costs, offset by higher credit loss and interest costs. It reaffirmed 2026 guidance of $2.81 to $2.91 per share and a 2026-2029 5% to 7% annualized growth target. Exelon also discussed a $41B capital plan, PJM capacity stress, and a 500 MW NJ battery project.

$EXCMedAI 8/10

Exelon (EXC) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 10 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Ryan Brown President and Chief Executive Officer - Calvin Butler Chief Financial Officer - Jeanne Jones President and Chief Executive Officer of PECO - Michael A.

$EXCMed

Exelon's Q2 Earnings In Line With Estimates, Revenues Rise Y/Y

Exelon Corporation EXC reported second-quarter 2026 adjusted operating earnings of 43 cents per share, in line with the Zacks Consensus Estimate. Earnings increased 10.3% from 39 cents in the year-ago quarter. Higher distribution and transmission rates across several utilities supported the improvement. On a GAAP basis, earnings were 39 cents per share, matching the year-ago quarter's reported figure.

$EXCMedAI 8/10

[EXC Q2 2026 Earnings Call] Exelon Counters PJM Grid Stress with $1B Battery Storage as Simulated Prices Hit $777/MW-Day — BigGo Finance

[EXC Q2 2026 Earnings Call] Exelon Counters PJM Grid Stress with $1B Battery Storage as Simulated Prices Hit $777/MW-Day Exelon’s second-quarter earnings call was less about the numbers and more about the grid that hosts them. The $0.43 per share print was squarely in line with expectations and triggered a reaffirmation of full-year guidance. But it was the alarming deterioration in PJM’s supply-demand balance—and Exelon’s aggressive, multi-pronged response—that set the tone.

$AMGNMed

Amgen (AMGN) Is Up 6.7% After EMA Backs Broader Repatha Use in High-Risk Patients – Has The Bull Case Changed?

Amgen (AMGN) shares rose about 6.7% after the EMA CHMP issued a positive opinion to expand Repatha’s use in Europe for adults with or at high risk for atherosclerotic cardiovascular disease, based on Phase 3 VESALIUS-CV results. If approved by the European Commission, it could widen the eligible patient pool. The article cites Q2 2026 revenue of $10,054 million and net income of $2,375 million.